Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumetinib in advanced MET-altered non-small cell lung cancer
jRCT2051200072Phase 2Active, not recruiting
- Sponsor
- Haihe
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of glumetinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Haihe. Primary endpoint: Objective response rate. Started Nov 2020; status: active, not recruiting.
02
Drugs
glumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051200072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200072.